ScholarIQanswers from OpenAlex & ORCID
Olalekan O. Oluwole
ResearcherPublications, citations & collaboration network
Olalekan O. Oluwole is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Olalekan O. Oluwole have?
ScholarIQindexed works
Olalekan O. Oluwole has 379 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Olalekan O. Oluwole have?
ScholarIQcitation count
Olalekan O. Oluwole has 21,289 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Olalekan O. Oluwole?
ScholarIQh-index
Olalekan O. Oluwole has an h-index of 49 in OpenAlex.
What is the i10-index of Olalekan O. Oluwole?
ScholarIQi10-index
Olalekan O. Oluwole has an i10-index of 134 in OpenAlex.
What is the ORCID of Olalekan O. Oluwole?
ScholarIQorcid
The ORCID for Olalekan O. Oluwole is on the source record.
What is the OpenAlex record for Olalekan O. Oluwole?
ScholarIQopenalex
The OpenAlex for Olalekan O. Oluwole is on the source record.
What are the most-cited papers on Olalekan O. Oluwole?
ScholarIQmost cited works
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano J. Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew J. Frigault, Brianna Hoffner, Christopher Hoimes, Mario E. Lacouture, Frederick L. Locke, Matthew A. Lunning, Nisha Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan O. Oluwole, Sandip Pravin Patel, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Momen M. Wahidi, Yinghong Wang, Alyse Johnson-Chilla, Jillian L. Scavone
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano J. Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew J. Frigault, Benjamin H. Kaffenberger, Matthew A. Lunning, Suzanne McGettigan, Jordan P. McPherson, Nisha Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan O. Oluwole, Sandip Pravin Patel, Nathan A. Pennell, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Ryan Weight, Alyse Johnson-Chilla, Griselda Zuccarino-Catania, Anita M. Engh
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Amaka Achufusi, Philippe Armand, Meghan Berkenstock, Shailender Bhatia, Lihua E. Budde, Saurin Chokshi, Marianne Davies, Amro Elshoury, Yaron Gesthalter, Aparna Hegde, Michael D. Jain, Benjamin H. Kaffenberger, Melissa G. Lechner, Tianhong Li, Alissa Marr, Suzanne McGettigan, Jordan P. McPherson, Theresa Medina, Nisha Mohindra, Anthony J. Olszanski, Olalekan O. Oluwole, Sandip Pravin Patel, Pradnya D. Patil, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Vlad G. Zaha, Megan Lyons, Mary A. Dwyer, Lisa Hang
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
Olalekan O. Oluwole, Krimo Bouabdallah, Javier Muñoz, Sophie de Guibert, Julie M. Vose, Nancy L. Bartlett, Yi Lin, Abhinav Deol, Peter A. McSweeney, André Goy, Marie José Kersten, Caron A. Jacobson, Umar Farooq, Monique C. Minnema, Catherine Thiéblemont, John M. Timmerman, Patrick J. Stiff, Irit Avivi, Dimitrios Tzachanis, Jaeyeon Kim, Zahid Bashir, Jeff McLeroy, Yan Zheng, John M. Rossi, Lisa D. Johnson, Lovely Goyal, Tom van Meerten